<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04892953</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1031</org_study_id>
    <secondary_id>NCI-2021-03777</secondary_id>
    <secondary_id>2020-1031</secondary_id>
    <nct_id>NCT04892953</nct_id>
  </id_info>
  <brief_title>Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy</brief_title>
  <official_title>Local Consolidative Therapy (LCT) and Durvalumab (MEDI4736) for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (ENDURE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial finds out the effect of local consolidative therapy and durvalumab in&#xD;
      treating patients with stage III non-small cell lung cancer that has 3 or fewer lesions of&#xD;
      progression (oligoprogressive) and greater than 3 lesions of progression (polyprogressive)&#xD;
      after chemoradiation and anti-PD-l1 therapy. Local consolidative therapy, such as surgery&#xD;
      and/or radiation, after initial treatment may kill any remaining tumor cells. Immunotherapy&#xD;
      with durvalumab, may induce changes in body's immune system and may interfere with the&#xD;
      ability of tumor cells to grow and spread. Giving local consolidative therapy and durvalumab&#xD;
      may help to control the disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the efficacy of local consolidative therapy (LCT) followed by durvalumab for&#xD;
      oligoprogressive non-small cell lung cancer (NSCLC) compared to historical standard control&#xD;
      in terms of progression-free survival (PFS).&#xD;
&#xD;
      II. To determine the efficacy of LCT followed by chemotherapy and durvalumab for&#xD;
      polyprogressive NSCLC compared to historical standard control in terms of PFS.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the efficacy of LCT followed by durvalumab for oligoprogressive NSCLC&#xD;
      compared to historical standard control in terms of overall survival (OS)1.&#xD;
&#xD;
      II. To determine the efficacy of LCT followed by chemotherapy and durvalumab for&#xD;
      polyprogressive NSCLC compared to historical standard control in terms of OS1.&#xD;
&#xD;
      III. To determine the efficacy of LCT followed by durvalumab for oligoprogressive NSCLC&#xD;
      compared to historical standard control in terms of OS2.&#xD;
&#xD;
      IV. To determine the efficacy of LCT followed by chemotherapy and durvalumab for&#xD;
      polyprogressive NSCLC compared to historical standard control in terms of OS2.&#xD;
&#xD;
      V. To assess patterns of failure after LCT followed by durvalumab for oligoprogressive NSCLC.&#xD;
&#xD;
      VI. To assess patterns of failure of LCT followed by chemotherapy and durvalumab for&#xD;
      polyprogressive NSCLC.&#xD;
&#xD;
      VII. To assess quality of life of LCT followed by durvalumab for oligoprogressive NSCLC.&#xD;
&#xD;
      VIII. To assess quality of life of LCT followed by chemotherapy and durvalumab for&#xD;
      polyprogressive NSCLC.&#xD;
&#xD;
      SAFETY OBJECTIVES:&#xD;
&#xD;
      I. To assess the safety and tolerability profile of LCT followed by durvalumab for&#xD;
      oligoprogressive NSCLC.&#xD;
&#xD;
      II. To assess the safety and tolerability profile of LCT followed by chemotherapy and&#xD;
      durvalumab for polyprogressive NSCLC.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Biomarker analyses on tumor biopsies pre-radiation, while on systemic therapy (cycle 2),&#xD;
      and optional at progression, as well as blood collections pre-radiation, pre-durvalumab,&#xD;
      while on systemic therapy (cycle 2), every other restaging scan, and optional at progression.&#xD;
&#xD;
      II. Microbiome analyses on stool sample pre-radiation, pre-systemic therapy, and at&#xD;
      progression.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 2 cohorts.&#xD;
&#xD;
      COHORT A (OLIGOPROGRESSIVE): Patients undergo LCT consisting of radiation therapy and/or&#xD;
      surgery, then receive durvalumab intravenously (IV) over 1 hour on day 1. Cycles repeat every&#xD;
      28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      COHORT B (POLYPROGRESSIVE): Patients undergo LCT consisting of radiation therapy and/or&#xD;
      surgery, then receive durvalumab IV over 1 hour on day 1. Patients also receive one of the&#xD;
      following chemotherapy options: carboplatin and paclitaxel on day 1, carboplatin on day 1 and&#xD;
      nab-paclitaxel on days 1, 8, 15, or carboplatin on day 1 and gemcitabine on days 1 and 8.&#xD;
      Treatment repeats every 21 days for 4 cycles in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients with non-squamous histology receive pemetrexed on day 1 every&#xD;
      21 days for cycles 1-4, pemetrexed and durvalumab IV on day 1 every 28 days in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 12 weeks for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From local consolidative therapy (LCT) initiation until progression or death, assessed up to 2 years</time_frame>
    <description>The Kaplan-Meier product-limit estimate of the PFS function will be estimated and displayed for each treatment group. The median PFS time will be given with 95% confidence interval. Summaries of the number and percentage of patients experiencing a PFS event, and the type of event (Response Evaluation Criteria in Solid Tumors version 1.1 or death) will be provided. As comparative analysis, the one-sample log-rank test will be used to test difference in PFS between treatment and the historical control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)1</measure>
    <time_frame>From diagnosis to death, assessed up to 2 years</time_frame>
    <description>Will be estimated in each study cohort by Kaplan-Meier estimate. Summaries of the number and percentage of patients who have died, are still in survival follow-up, are lost to follow-up and have withdrawn consent will be provided along with median OS. Furthermore, one-sample log-rank test will be used to test difference in OS between treatment and historical control. Multivariate Cox proportional hazards model will be fitted to investigate the association between OS1/OS2 and other important prognostic variables such as age, histology, and gender.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS2</measure>
    <time_frame>From LCT initiation until death, assessed up to 2 years</time_frame>
    <description>Will be estimated in each study cohort by Kaplan-Meier estimate. Summaries of the number and percentage of patients who have died, are still in survival follow-up, are lost to follow-up and have withdrawn consent will be provided along with median OS. Furthermore, one-sample log-rank test will be used to test difference in OS between treatment and historical control. Multivariate Cox proportional hazards model will be fitted to investigate the association between OS1/OS2 and other important prognostic variables such as age, histology, and gender.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of intralobar progression</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be determined by surveillance imaging. Will be assessed using Kaplan-Meier estimate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of mediastinal progression</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be determined by surveillance imaging. Will be assessed using Kaplan-Meier estimate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of distant progression</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be determined by surveillance imaging. Will be assessed using Kaplan-Meier estimate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaires</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will include MDA Symptom Inventory - Lung Cancer mean score and standard deviation for each time point. The trajectory and trend of QOL will also be assessed by plotting MDASI-LC score vs time by treatment arm. The impact of patient and treatment characteristics will be evaluated by other analyses such as area under the curve and linear mixed models.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Stage III Lung Cancer AJCC v8</condition>
  <condition>Stage III Lung Non-Small Cell Cancer AJCC v7</condition>
  <condition>Stage IIIA Lung Cancer AJCC v8</condition>
  <condition>Stage IIIA Lung Non-Small Cell Cancer AJCC v7</condition>
  <condition>Stage IIIB Lung Cancer AJCC v8</condition>
  <condition>Stage IIIB Lung Non-Small Cell Cancer AJCC v7</condition>
  <condition>Stage IIIC Lung Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Cohort A (oligoprogressive)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo LCT consisting of radiation therapy and/or surgery, then receive durvalumab IV over 1 hour on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (polyprogressive)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo LCT consisting of radiation therapy and/or surgery, then receive durvalumab IV over 1 hour on day 1. Patients also receive one of the following chemotherapy options: carboplatin and paclitaxel on day 1, carboplatin on day 1 and nab-paclitaxel on days 1, 8, 15, or carboplatin on day 1 and gemcitabine on days 1 and 8. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with non-squamous histology receive pemetrexed on day 1 every 21 days for cycles 1-4, pemetrexed and durvalumab IV on day 1 every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort B (polyprogressive)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carboplatinum</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort A (oligoprogressive)</arm_group_label>
    <arm_group_label>Cohort B (polyprogressive)</arm_group_label>
    <other_name>Imfinzi</other_name>
    <other_name>Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer</other_name>
    <other_name>MEDI-4736</other_name>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort B (polyprogressive)</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Local Consolidation Therapy</intervention_name>
    <description>Undergo LCT</description>
    <arm_group_label>Cohort A (oligoprogressive)</arm_group_label>
    <arm_group_label>Cohort B (polyprogressive)</arm_group_label>
    <other_name>LCT</other_name>
    <other_name>Local Consolidative Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort B (polyprogressive)</arm_group_label>
    <other_name>ABI 007</other_name>
    <other_name>ABI-007</other_name>
    <other_name>Abraxane</other_name>
    <other_name>Albumin-bound Paclitaxel</other_name>
    <other_name>Albumin-Stabilized Nanoparticle Paclitaxel</other_name>
    <other_name>Nanoparticle Albumin-bound Paclitaxel</other_name>
    <other_name>Nanoparticle Paclitaxel</other_name>
    <other_name>Paclitaxel Albumin</other_name>
    <other_name>paclitaxel albumin-stabilized nanoparticle formulation</other_name>
    <other_name>Protein-bound Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort B (polyprogressive)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>Bristaxol</other_name>
    <other_name>Praxel</other_name>
    <other_name>Taxol</other_name>
    <other_name>Taxol Konzentrat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort B (polyprogressive)</arm_group_label>
    <other_name>MTA</other_name>
    <other_name>Multitargeted Antifolate</other_name>
    <other_name>Pemfexy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Complete questionnaire</description>
    <arm_group_label>Cohort A (oligoprogressive)</arm_group_label>
    <arm_group_label>Cohort B (polyprogressive)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Complete questionnaire</description>
    <arm_group_label>Cohort A (oligoprogressive)</arm_group_label>
    <arm_group_label>Cohort B (polyprogressive)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the informed consent form (ICF) and in this&#xD;
             protocol&#xD;
&#xD;
          -  Stage III NSCLC (AJCC 7th and 8th edition) patients who received standard&#xD;
             chemoradiation followed by durvalumab therapy with either progressive disease or&#xD;
             persistent disease. Persistent disease defined as residual positron emission&#xD;
             tomography (PET) avidity 6 months after completion of initial definitive therapy and&#xD;
             confirmed with biopsy&#xD;
&#xD;
          -  For lung adenocarcinoma patients, patients must not harbor any EGFR sensitizing&#xD;
             mutations, ALK fusion, ROS1 rearrangements, RET fusions, or MET exon 14 skipping&#xD;
             mutations where there are standard of care therapy options available. For patients&#xD;
             with histologies other than adenocarcinoma, EGFR and ALK status is not required.&#xD;
             Adenocarcinoma patients may be consented prior to the EGFR, ALK, and ROS1 status being&#xD;
             known, but EGFR, ALK, and ROS1 status must be determined prior to initiating therapy.&#xD;
             EGFR, ALK, and ROS ALK status may be determined using either tumor- or plasma-based,&#xD;
             Clinical Laboratory Improvement Act (CLIA)-certified assays. For patients with NSCLC,&#xD;
             not otherwise specified (NOS), EGFR testing is not required, as the frequency of&#xD;
             alterations is exceedingly rare in this histology&#xD;
&#xD;
          -  Cohort A: Oligoprogressive disease is defined as having 3 or fewer lesions of&#xD;
             progression (sites can be local, distant, or both). Multiple mediastinal lesions will&#xD;
             be counted as 1 lesion&#xD;
&#xD;
          -  Cohort B: Polyprogressive disease defined as having greater than 3 lesions of&#xD;
             progression (sites can be local, distant, or both). Multiple mediastinal lesions will&#xD;
             be counted as 1 lesion&#xD;
&#xD;
          -  Candidate for radiation therapy to at least one lesion&#xD;
&#xD;
          -  Tumor assessment by computed tomography (CT) scan with contrast chest/abdomen/pelvis&#xD;
             or PET-CT, and magnetic resonance imaging (MRI) brain must be performed within 28 days&#xD;
             prior to study entry&#xD;
&#xD;
          -  Age &gt;= 18 years at time of study entry&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          -  Body weight &gt; 30 kg&#xD;
&#xD;
          -  Hemoglobin &gt;= 9.0 g/dL&#xD;
&#xD;
          -  Platelet count &gt;= 75 Ã— 10^9/L&#xD;
&#xD;
          -  Serum bilirubin =&lt; 1.5 x institutional upper limit of normal (ULN). This will not&#xD;
             apply to patients with confirmed Gilbert's syndrome (persistent or recurrent&#xD;
             hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or&#xD;
             hepatic pathology), who will be allowed only in consultation with their physician&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 2.5 x institutional upper limit of normal unless liver metastases are present, in&#xD;
             which case it must be =&lt; 5 x ULN&#xD;
&#xD;
          -  Measured creatinine clearance (CL) &gt; 15 mL/min or calculated creatinine CL &gt; 15 mL/min&#xD;
             by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine&#xD;
             collection for determination of creatinine clearance&#xD;
&#xD;
          -  Patient is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up&#xD;
&#xD;
          -  Must have a life expectancy of at least 12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who rapidly progressed on the PACIFIC regimen (chemoradiotherapy [CRT] +&#xD;
             durvalumab). This is defined as any progression on the first 3-month imaging scan&#xD;
             after starting durvalumab post-CRT&#xD;
&#xD;
          -  Patients who were treated with anti-PD-(L)1 therapy other than durvalumab&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product during the&#xD;
             last 4 weeks&#xD;
&#xD;
          -  Concurrent enrolment in another clinical study, unless it is an observational&#xD;
             (non-interventional) clinical study. No other investigational therapy is permitted&#xD;
             after durvalumab and start of this protocol&#xD;
&#xD;
          -  Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine&#xD;
             therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal&#xD;
             antibodies) =&lt; 28 days prior to the first dose of study drug. This 28 day washout&#xD;
             period is not required for durvalumab. If sufficient wash-out time has not occurred&#xD;
             due to the schedule or pharmacokinetic (PK) properties of an agent, a longer wash-out&#xD;
             period will be required, as agreed by AstraZeneca and the investigator&#xD;
&#xD;
          -  Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria&#xD;
             for Adverse Events (CTCAE) grade &gt;= 2 from previous anticancer therapy with the&#xD;
             exception of alopecia, vitiligo, and the laboratory values defined in the inclusion&#xD;
             criteria&#xD;
&#xD;
               -  Patients with grade &gt;= 2 neuropathy will be evaluated on a case-by-case basis&#xD;
                  after consultation with the study physician&#xD;
&#xD;
               -  Patients with irreversible toxicity not reasonably expected to be exacerbated by&#xD;
                  treatment with durvalumab may be included only after consultation with the study&#xD;
                  physician&#xD;
&#xD;
          -  Any concurrent chemotherapy (with the exception of protocol directed chemotherapy in&#xD;
             the polyprogression cohort), investigational product (IP), biologic, or hormonal&#xD;
             therapy for cancer treatment. Concurrent use of hormonal therapy for&#xD;
             non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable&#xD;
&#xD;
          -  Major surgical procedure (as defined by the investigator) within 28 days prior to the&#xD;
             first dose of IP. Note: Local surgery of isolated lesions for palliative intent is&#xD;
             acceptable&#xD;
&#xD;
          -  History of allogenic organ transplantation&#xD;
&#xD;
          -  Active or prior documented autoimmune or inflammatory disorders (including&#xD;
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with&#xD;
             the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,&#xD;
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid&#xD;
             arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this&#xD;
             criterion:&#xD;
&#xD;
               -  Patients with vitiligo or alopecia&#xD;
&#xD;
               -  Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on&#xD;
                  hormone replacement&#xD;
&#xD;
               -  Any chronic skin condition that does not require systemic therapy&#xD;
&#xD;
               -  Patients without active disease in the last 5 years may be included but only&#xD;
                  after consultation with the study physician&#xD;
&#xD;
               -  Patients with celiac disease controlled by diet alone&#xD;
&#xD;
          -  Uncontrolled intercurrent illness, including but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable&#xD;
             angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic&#xD;
             gastrointestinal conditions associated with diarrhea, or psychiatric illness/social&#xD;
             situations that would limit compliance with study requirement, substantially increase&#xD;
             risk of incurring adverse events (AEs) or compromise the ability of the patient to&#xD;
             give written informed consent&#xD;
&#xD;
          -  History of another primary malignancy except for&#xD;
&#xD;
               -  Malignancy treated with curative intent and with no known active disease &gt;= 3&#xD;
                  years before the first dose of IP and of low potential risk for recurrence&#xD;
&#xD;
               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease&#xD;
&#xD;
               -  Adequately treated carcinoma in situ without evidence of disease&#xD;
&#xD;
          -  History of leptomeningeal carcinomatosis&#xD;
&#xD;
          -  Patients with suspected brain metastases at screening should have an MRI (preferred)&#xD;
             or CT each preferably with IV contrast of the brain prior to study entry. Brain&#xD;
             metastases must be treated prior to enrolment and demonstrate radiographic stability&#xD;
             (defined as 2 brain images, both of which are obtained after treatment to the brain&#xD;
             metastases. These imaging scans should both be obtained at least four weeks apart and&#xD;
             show no evidence of intracranial progression). Treated brain metastases will be&#xD;
             counted as lesions treated as part of the protocol. In addition, any neurologic&#xD;
             symptoms that developed either as a result of the brain metastases or their treatment&#xD;
             must have resolved or be stable either, without the use of steroids, or are stable on&#xD;
             a steroid dose of =&lt; 10mg/day of prednisone or its equivalent and anticonvulsants for&#xD;
             at least 14 days prior to the start of treatment&#xD;
&#xD;
          -  Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) &gt;= 470 ms&#xD;
             calculated from 3 electrocardiograms (ECGs) (within 15 minutes at 5 minutes apart)&#xD;
&#xD;
          -  History of active primary immunodeficiency&#xD;
&#xD;
          -  Active infection including tuberculosis (clinical evaluation that includes clinical&#xD;
             history, physical examination and radiographic findings, and tuberculosis (TB) testing&#xD;
             in line with local practice), hepatitis B (known positive hepatitis B virus [HBV]&#xD;
             surface antigen (HBsAg) result), hepatitis C patients with a past or resolved HBV&#xD;
             infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence&#xD;
             of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible&#xD;
             only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA)&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 14 days before the first&#xD;
             dose of durvalumab. The following are exceptions to this criterion:&#xD;
&#xD;
               -  Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra&#xD;
                  articular injection)&#xD;
&#xD;
               -  Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of&#xD;
                  prednisone or its equivalent&#xD;
&#xD;
               -  Steroids as premedication for hypersensitivity reactions (e.g., CT scan&#xD;
                  premedication)&#xD;
&#xD;
          -  Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note:&#xD;
             Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to&#xD;
             30 days after the last dose of IP&#xD;
&#xD;
          -  Female patients who are pregnant or breastfeeding or male or female patients of&#xD;
             reproductive potential who are not willing to employ effective birth control from&#xD;
             screening to 90 days after the last dose of durvalumab monotherapy&#xD;
&#xD;
          -  Known allergy or hypersensitivity to any of the study drugs or any of the study drug&#xD;
             excipients&#xD;
&#xD;
          -  Patients who have received prior anti-PD-1, anti PD-L1 or anti CTLA-4:&#xD;
&#xD;
               -  Must not have experienced a toxicity that led to permanent discontinuation of&#xD;
                  prior immunotherapy&#xD;
&#xD;
               -  All AEs while receiving prior immunotherapy must have completely resolved or&#xD;
                  resolved to baseline prior to screening for this study&#xD;
&#xD;
               -  Must not have experienced a &gt;= grade 3 immune related AE or an immune related&#xD;
                  neurologic or ocular AE of any grade while receiving prior immunotherapy. NOTE:&#xD;
                  Patients with endocrine AE of =&lt; grade 2 are permitted to enroll if they are&#xD;
                  stably maintained on appropriate replacement therapy and are asymptomatic&#xD;
&#xD;
               -  Must not have required the use of additional immunosuppression other than&#xD;
                  corticosteroids for the management of an AE, not have experienced recurrence of&#xD;
                  an AE if re-challenged, and not currently require maintenance doses of &gt; 10 mg&#xD;
                  prednisone or equivalent per day&#xD;
&#xD;
          -  Judgment by the investigator that the patient is unsuitable to participate in the&#xD;
             study and the patient is unlikely to comply with study procedures, restrictions and&#xD;
             requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Percy P Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Percy P. Lee</last_name>
      <phone>713-563-2300</phone>
    </contact>
    <investigator>
      <last_name>Percy P. Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

